Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses current developments in myeloproliferative neoplasms (MPNs) at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) held in Glasgow, Scotland. According to Dr Mesa, it is a very exciting time for MPNs as new JAK inhibitors such as pacritinib and NS-018, anti-fibrosing agents such as PRM-151 as well as telomerase inhibitors such as imetelstat, are being developed.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates